Oren Gilad - Mar 28, 2024 Form 4 Insider Report for Aprea Therapeutics, Inc. (APRE)

Role
President, CEO, Director
Signature
/s/ John Hamill, Attorney-in-Fact
Stock symbol
APRE
Transactions as of
Mar 28, 2024
Transactions value $
$0
Form type
4
Date filed
3/28/2024, 05:57 PM
Previous filing
Mar 14, 2024
Next filing
Oct 15, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APRE Common Stock Award $0 +6.73K +2.07% $0.00 331K Mar 28, 2024 Direct F1
holding APRE Common Stock 1.2K Mar 28, 2024 By daughter F2
holding APRE Common Stock 600 Mar 28, 2024 By son F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APRE Stock Options (Right to Buy) Award $0 +26.9K $0.00 26.9K Mar 28, 2024 Common Stock 26.9K $6.69 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares represent restricted stock units ("RSUs") and shall vest and be settled in the Issuer's common stock ("Common Stock") in three (3) equal annual installments beginning on March 28, 2025, until vested in full, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.
F2 The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
F3 Twenty-five percent of these options vest on March 28, 2025, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.